| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 72, 1328-1331, Copyright © 1991 by Endocrine Society
ARTICLES |
GK Huber, P Fong, ES Concepcion and TF Davies
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029.
We have assessed the bioactivity of newly available recombinant human TSH (rec-hTSH) using human fetal thyroid cells, with the longer term aim of assessing its use for clinical applications. Rec-hTSH caused a consistent and dose-related increase in thyroid monolayer cell cAMP release and human thyroglobulin (hTg) secretion, confirming its bioactivity. Repetitive studies (n = 5) allowed us to derive an estimated biopotency for the rec-hTSH preparation examined of 5.6 IU/mg compared to 10 IU/mg for commercially available bovine TSH for human use. The rec-hTSH had a bioimmune ratio of 0.55, similar to that of purified pituitary hTSH standards, Furthermore, rec-hTSH induced thyroid epithelial cell growth, as evidenced by a decrease in thyroid cell doubling time from 54 +/- 2.1 to 31 +/- 1.7 h (P less than 0.005). Hence, rec-hTSH is a potent glycoprotein hormone preparation when measured in a homologous human thyroid cell culture system. Rec-hTSH could serve as a future definitive International Standard and has the potential for a useful diagnostic and therapeutic reagent.
This article has been cited by other articles:
![]() |
R.-Y. Lin, A. Kubo, G. M. Keller, and T. F. Davies Committing Embryonic Stem Cells to Differentiate into Thyrocyte-Like Cells in Vitro Endocrinology, June 1, 2003; 144(6): 2644 - 2649. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF] |
||||
![]() |
M. Braga, M. D. Ringel, and D. S. Cooper Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5148 - 5151. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kimura, A. Van Keymeulen, J. Golstein, A. Fusco, J. E. Dumont, and P. P. Roger Regulation of Thyroid Cell Proliferation by TSH and Other Factors: A Critical Evaluation of in Vitro Models Endocr. Rev., October 1, 2001; 22(5): 631 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Vargas, H. Uy, C. Bazan, T. A. Guise, and J. M. Bruder Hemiplegia after Thyrotropin Alfa in a Hypothyroid Patient with Thyroid Carcinoma Metastatic to the Brain J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3867 - 3871. [Full Text] |
||||
![]() |
B. R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P. W. Ladenson, S. I. Sherman, D. S. Cooper, K. E. Graham, L. E. Braverman, M. C. Skarulis, et al. A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3877 - 3885. [Abstract] [Full Text] |
||||
![]() |
P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri, F. Brucker-Davis, D. S. Cooper, J. R. Garber, F. E. Wondisford, T. F. Davies, L. J. DeGroot, G. H. Daniels, et al. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma N. Engl. J. Med., September 25, 1997; 337(13): 888 - 896. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |